Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06559163 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Obexelimab in Patients With Systemic Lupus Erythematosus

Study acronym: SunStone
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 18, 2026 (before its estimated September 2026 completion). Its status may not reflect the trial's current state.
Trial flagged as At Risk
Primary completion moved at least 2 months later Jun 2026 → Sep 2026
See other at-risk trials from Zenas BioPharma (USA), LLC

Record History

  1. Enrollment closed, study ongoing Primary completion pushed from Jun 2026 to Sep 2026 · Trial sites expanded: 82 → 110 locations · Completion pushed from Sep 2026 to Dec 2026v11 Show 3 more changesShow less
    • Primary completion pushed from Jun 2026 to Sep 2026
    • Trial sites expanded: 82 → 110 locations
    • Completion pushed from Sep 2026 to Dec 2026
  2. Study sites: 56 to 82v10
  3. Study sites: 47 to 56v9
  4. Study sites: 36 to 47v8
  5. Primary completion date: Nov 2025 to Jun 2026 Completion date: Mar 2026 to Sep 2026 · Site details revised at 2 of 36 sitesv7 Show 2 more changesShow less
    • Completion date: Mar 2026 to Sep 2026
    • Site details revised at 2 of 36 sites
Show 5 earlier versionsHide 5 earlier versions
  1. Study sites: 15 to 36v6
  2. Study sites: 9 to 15v5
  3. Study sites: 8 to 9v4
  4. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 8 · Start date changed from estimate of Aug 2024 to Sep 17, 2024v3 Show 2 more changesShow less
    • Study sites: 0 to 8
    • Start date changed from estimate of Aug 2024 to Sep 17, 2024
  5. Study title shortened, about 2 wordsv2 See this version in full on ClinicalTrials.gov ↗
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to examine the efficacy and safety of obexelimab in participants with systemic lupus erythematosus (SLE).
Trial Details
NCT Number NCT06559163
Lead Sponsor Zenas BioPharma (USA), LLC
Conditions Systemic Lupus Erythematosus
Enrollment 190 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov